Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT
Stanford University
Stanford University
Stanford University
Fred Hutchinson Cancer Center
Massachusetts General Hospital
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins